Aripiprazole (129722-12-9) 's Synthetic route

Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D₂ Receptor (D₂R) Biased Agonism

Bonifazi, Alessandro  Yano, Hideaki  Ellenberger, Michael P.  Muller, Ludovic  Kumar, Vivek  Zou, Mu-Fa  Cai, Ning Sheng  Guerrero, Adrian M.  Woods, Amina S.  Shi, Lei  Newman, Amy Hauck

The development of bivalent ligands has attracted interest as a way to potentially improve the selectivity and/or affinity for a specific receptor subtype. The ability to bind two distinct receptor binding sites simultaneously can allow the selective activation of specific G-protein dependent or β-arrestin-mediated cascade pathways. Herein, we developed an extended SAR study using sumanirole (1) as the primary pharmacophore. We found that substitutions in the N-1- and/or N-5-positions, physiochemical properties of those substituents, and secondary aromatic pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by G_i/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment. Compound 19 was identified as a new lead for its selective D₂ G-protein biased agonism with an EC₅₀ in the subnanomolar range. Structure-activity correlations were observed between substitutions in positions N-1 and/or N-5 of 1 and the capacity of the new bivalent compounds to selectively activate G-proteins versus β-arrestin recruitment in D₂R-BRET functional assays.